Metastatic Renal Cell Carcinoma Clinical Trial
— BERATOfficial title:
A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)
Verified date | February 2019 |
Source | Central European Society for Anticancer Drug Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sequential therapy with BEvacizumab, RAd001 (everolimus) and Tyrosinekinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
Status | Completed |
Enrollment | 22 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed Informed Consent - Documented progressive disease prior to study inclusion. - Adult males and females: = 18 years of age. - Metastatic or locally advanced RCC, not amendable to surgery with curative intention. - ECOG performance status 0-1. - Patients with measurable disease (at least one uni-dimensionally measurable target lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: = 1 measurable lesion that has not been irradiated. Patients with bone lesions as the only measurable lesion are eligible, provided that lesions consist of soft tissue, which is assessed via CT or MRI. - Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery 2 weeks) prior to start of treatment and patient recovered from toxic effects. - Modified MSKCC risk (according to Heng): good or intermediate. - White blood cell count (WBC) = 4x10*9/L with neutrophils = 1.5 x 10*9/L, platelet count = 100x10*9/L, hemoglobin = 9 g/dL. - Total bilirubin = 2 x upper limit of normal. - AST and ALT = 2.5 x upper limit of normal, or = 5 x upper limit of normal in case of liver metastases. - Serum creatinine = 2 x upper limit of normal or calculated creatinine clearance >30 ml/min. - International Normalized Ratio (INR) =1.5 except for patients on stable anticoagulant therapy. Activated partial thromboplastin time (aPTT) =1.5 times upper limit of normal (ULN) or greater than the lower limit of the therapeutic range. Note: The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the treatment start. - Adequate cardiac function (left ventricular ejection fraction =50% as assessed by ECHO) Exclusion Criteria: - Any investigational drug within the 30 days before inclusion. - Known or suspected allergy or hypersensitivity reaction to any of the components of study treatments or their excipients. - Pregnancy (absence to be confirmed by beta-hCG test) or lactation period. - Men or women of child-bearing potential who are sexually active and unwilling to use a highly effective method of contraception (Pearl index < 1%) during the trial. Oral contraceptives are acceptable if a barrier method is applied in conjunction. - Clinically symptomatic brain or meningeal metastasis (known or suspected), unless completion of local therapy for at least 3 months with discontinuation of steroids prior to start of treatment. - Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers, digoxin or digitoxin). - History of any of the following cardiac events within the past 6 months: 1. myocardial infarction (including severe/unstable angina), 2. coronary/peripheral artery bypass graft, 3. congestive heart failure (CHF) (NYHA Class III, or IV), 4. cerebrovascular accident, 5. transient ischemic attack, 6. pulmonary embolism, abdominal or tracheo-oesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess - Hemorrhage = grade 3 or clinically significant hemoptysis within the past 4 weeks - Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below 90 mm Hg despite the use of = 3 anti-hypertensive drugs). - History of relevant pulmonary hypertension or interstitial lung disease or severely impaired lung function. - Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or chronic diarrhea. - Previous malignancy (other than renal cell cancer) in the last 3 years, except basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a prostate carcinoma or superficial bladder tumor [Ta, Tis and T1]. - History of organ allograft. - Significant disease which, in the investigator's opinion would exclude the patient from the study. - Medication that is known to interfere with any of the agents applied in the trial. - Patients with a serious non-healing wound, ulcer or bone fracture. - Patients with a history of seizure(s) not controlled with standard medical therapy. - Patients receiving chronic systemic treatment with corticosteroids (dose of > 20 mg/day methylprednisone equivalent) or another immune-suppressive agent. Inhaled and topical steroids are acceptable. - Legal incapacity or limited legal capacity. - Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent. - Significant vascular disease (e.g. aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease. - Evidence or history of recurrent thromboembolism (>1 episode of deep venous thrombosis/peripheral embolism = CTCAE Grade 3) during the past 2 years, bleeding diathesis or coagulopathy. - Poorly controlled diabetes as defined by fasting serum glucose > 2.0 x ULN. - Active (acute or chronic) or uncontrolled infection of bacterial, mycotic or viral genesis. - Liver disease such as chronic active hepatitis or chronic persistent hepatitis. - Patients with a known history of HIV seropositivity. - QT prolongation (QTc > 450 msec). |
Country | Name | City | State |
---|---|---|---|
Germany | Charité Berlin | Berlin | |
Germany | University Hospital Bonn | Bonn | |
Germany | University Hospital Dresden | Dresden | |
Germany | University Hospital Düsseldorf | Düsseldorf | |
Germany | Waldkrankenhaus St. Marien | Erlangen | |
Germany | University Hospital Essen | Essen | |
Germany | University Hospital Frankfurt | Frankfurt | |
Germany | University Hospital Freiburg | Freiburg | |
Germany | University Hospital Göttingen | Göttingen | |
Germany | Oncological Practice Hannover | Hannover | |
Germany | University Hospital Hannover | Hannover | |
Germany | University Hospital Magdeburg | Magdeburg | |
Germany | University Hospital Tübingen | Tübingen |
Lead Sponsor | Collaborator |
---|---|
Central European Society for Anticancer Drug Research |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PFS rate of 2nd line treatment at 6 months after randomisation | PFS rate | 6 months after randomisation | |
Secondary | PFS for 2nd line treatment | PFS | after completion of second-line treatment (expected median treatment 1st and 2nd line: 16 months) | |
Secondary | PFS for each treatment given | PFS | after completion of each treatment line (expected median treatment duration 1st line: 11 months, 2nd line: 5 months, 3rd line: 6 months) | |
Secondary | Overall Survival | OS | after death of patient | |
Secondary | number and severity (CTCAE 4.0) adverse events | AE | continuously throughout trial | |
Secondary | changes in quality of life throughout the Trial using FKSI questionnaires | quality of life | continuously throughout trial (baseline, week 5, week 11, every 12 weeks, end of treatment for all treatment lines via FKSI-10 questionnaire) | |
Secondary | ORR for each treatment given | ORR | after completion of each treatment line (expected median treatment duration 1st line: 11 months, 2nd line: 5 months, 3rd line: 6 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00930033 -
Clinical Trial to Assess the Importance of Nephrectomy
|
Phase 3 | |
Recruiting |
NCT05863351 -
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
|
Phase 3 | |
Not yet recruiting |
NCT06284564 -
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
|
Phase 2 | |
Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
Active, not recruiting |
NCT03149822 -
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03647878 -
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
|
||
Completed |
NCT01517243 -
Phase II Study of Alternating Sunitinib and Temsirolimus
|
Phase 2 | |
Withdrawn |
NCT03927248 -
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02122003 -
Second Line Sorafenib After Pazopanib in Patients With RCC
|
Phase 2 | |
Completed |
NCT01182142 -
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
|
Phase 2 | |
Completed |
NCT00630409 -
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT04076787 -
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
|
||
Active, not recruiting |
NCT04467021 -
Cancer and Blood Pressure Management, CARISMA Study
|
N/A | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02282579 -
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
|
||
Terminated |
NCT02071641 -
Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT01342627 -
Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01274273 -
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00848640 -
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 |